Merck KGaA’s earnings beat consensus on lab equipment drug sales
Third-quarter earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for one-offs, rose 16.7% to 1.81 billion euros, surpassing the average estimate of 1.78 billion euros in an analyst poll on the company’s website.
The diversified group narrowed its full-year target range for adjusted EBITDA to between 6.80 billion and 7.20 billion euros, where it had previously forecast 6.75 billion to 7.25 billion.
FRANKFURT, Nov 10 (Reuters) – German healthcare and chemicals group Merck KGaA (MRCG.DE) on Thursday reported better-than-expected quarterly earnings on higher revenues from pharmaceuticals and biotech lab equipment .Third-quarter earnings before interest, taxes, depreciation and amortisation ( EBITDA ), adjusted for one-offs, rose 16.7% to 1.81 billion euros , surpassing the average estimate of 1.78 billion euros in an analyst poll on the company’s website.The diversified group narrowed its full-year target range for adjusted EBITDA to between 6.80 billion and 7.20 billion euros , where it had previously forecast 6.75 billion to 7.25 billion.
